Ipamorelin Research: Selective GH Secretagogue, GHS-R1a Agonism, and GH Axis Studies

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide GH secretagogue with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂. CAS 170851-70-4, molecular weight 711.85 Da. It was designed specifically to maximize GH secretagogue potency while minimizing off-target receptor stimulation, particularly ACTH and cortisol release observed with first-generation GHRPs. The result is one of the most receptor-selective GH secretagogues in the research literature.

Ipamorelin acts as an agonist at the ghrelin receptor (GHS-R1a), a class A GPCR expressed in the hypothalamus and pituitary, where it stimulates GH release through Gq-mediated signaling and downstream activation of PKC and intracellular calcium mobilization. Ipamorelin is available from Lone Star Peptide Co. at ≥99% HPLC purity. For researchers studying GH pulse dynamics, it pairs naturally with CJC-1295 to engage both GHRH and ghrelin receptor pathways simultaneously.

GHS-R1a Receptor Pharmacology

The ghrelin receptor (GHS-R1a) is expressed in the arcuate nucleus of the hypothalamus and in pituitary somatotrophs. Endogenous ghrelin activates this receptor to stimulate GH release through Gq coupling to phospholipase C, generating IP3 and DAG and mobilizing intracellular calcium from ER stores. This calcium signal triggers exocytosis of pre-formed GH secretory granules from pituitary somatotrophs.

Ipamorelin's GHS-R1a agonism follows this same pathway but with pharmacological properties that differ from ghrelin itself, higher selectivity for GHS-R1a over GHS-R1b (the truncated, non-signaling receptor isoform), improved resistance to protease degradation relative to the 28-amino acid ghrelin, and a more tractable molecular weight for cell culture dosing.

Selectivity vs GHRP-2 and GHRP-6

Ipamorelin was specifically engineered to be more selective than GHRP-2 and GHRP-6. GHRP-2 stimulates GH, cortisol (via ACTH), and prolactin; GHRP-6 stimulates GH and potently stimulates appetite via hypothalamic NPY activation. Ipamorelin stimulates GH with minimal cortisol, prolactin, or NPY co-stimulation in published animal model studies. This selectivity makes Ipamorelin the preferred GHS for research designs where isolated GH axis activation is required without confounding HPA axis or appetite pathway co-activation.

GH Pulse Dynamics Research

GH is secreted in discrete pulsatile bursts in vivo, with pulse amplitude and frequency regulated by the balance between GHRH (stimulatory) and somatostatin (inhibitory) inputs to somatotroph cells. Ipamorelin's ghrelin receptor agonism provides a pharmacological tool for studying the ghrelin/GHS-R1a contribution to GH pulse amplitude independent of the GHRH pathway.

In pituitary cell culture models, Ipamorelin treatment produces concentration-dependent GH release that peaks rapidly and returns to baseline, modeling the pulsatile profile of endogenous GH secretion. This pulsatile character, in contrast to sustained GH release from exogenous GH administration in parallel experiments, is of interest to researchers modeling physiological GH pulse architecture in vitro.

GHRH Receptor Pathway Synergy, CJC-1295 Combination

The two pharmacological inputs to pituitary GH release, GHRH receptor agonism and ghrelin/GHS-R1a agonism, are mechanistically complementary. GHRH (and its analog CJC-1295) acts through Gs/cAMP/PKA in somatotrophs; Ipamorelin acts through Gq/IP3/calcium. Research in pituitary cell models documents that simultaneous activation of both pathways produces GH release exceeding that of either compound alone: a synergistic or at minimum strongly additive response consistent with the convergence of two independent GH-stimulatory mechanisms at the somatotroph.

The CJC-1295/Ipamorelin pre-formulated blend provides researchers with both compounds for dual-pathway GH axis activation experiments.

Storage and Handling

Ipamorelin is supplied as a lyophilized white powder with good aqueous solubility. The non-natural amino acids in its sequence (D-2-Naphthylalanine, D-Phenylalanine, Aib) confer significant proteolytic resistance. Store at −20°C, protected from light and moisture. Reconstituted solutions are stable at 4°C for up to 7 days. Review storage best practices for handling peptides containing non-natural amino acids.

Key Takeaways

Ipamorelin is a selective GHS-R1a agonist designed specifically to avoid ACTH, cortisol, and prolactin co-stimulation seen with GHRP-2 and GHRP-6.

GHS-R1a activation in somatotrophs proceeds through Gq/PLC/IP3/calcium: a mechanistically distinct pathway from GHRH's Gs/cAMP/PKA signal.

GH pulse dynamics research benefits from Ipamorelin's pulsatile release profile, which mirrors physiological GH secretion patterns in vitro.

GHRH receptor (CJC-1295) and ghrelin receptor (Ipamorelin) co-activation produces synergistic GH release, documented across multiple pituitary cell model systems.

Non-natural amino acids in the sequence (D-2-Nal, D-Phe, Aib) confer significant proteolytic stability, distinguishing Ipamorelin from GHRP-2 and GHRP-6.

Ipamorelin at 711.85 Da is easier to work with analytically than larger GH-axis peptides, mass confirmation is straightforward and purity is reliably above 99%.

Frequently Asked Questions

What is Ipamorelin and what makes it selective?

Ipamorelin is a synthetic pentapeptide GH secretagogue and GHS-R1a agonist. CAS 170851-70-4. Its selectivity is the result of deliberate molecular design, it stimulates GH release via ghrelin receptor agonism with minimal co-stimulation of ACTH, cortisol, or prolactin pathways. This selectivity distinguishes it from GHRP-2 and GHRP-6. For in vitro research use only.

How does Ipamorelin differ from GHRP-2 and GHRP-6?

GHRP-2 stimulates GH, ACTH, and prolactin. GHRP-6 stimulates GH and potently activates NPY/appetite pathways. Ipamorelin stimulates GH with minimal cortisol, prolactin, or NPY co-activation, making it the preferred tool for research requiring isolated GH axis stimulation without confounding HPA axis or appetite signal contributions.

Why combine Ipamorelin with CJC-1295?

Ipamorelin activates the ghrelin receptor (GHS-R1a): a Gq-coupled pathway. CJC-1295 activates the GHRH receptor: a Gs-coupled pathway. These are mechanistically independent GH-stimulatory inputs that, when co-activated, produce synergistic GH release in pituitary cell models. Studying both together allows investigation of dual-pathway GH axis pharmacology.

How is Ipamorelin reconstituted?

Ipamorelin reconstitutes readily in sterile water or PBS. Add solvent gently along the vial wall. The compound's non-natural amino acids provide proteolytic resistance, but standard reconstitution protocols apply. For cell culture use, ensure sterile-filtered solvent.

Is Ipamorelin stable in solution?

Yes, Ipamorelin's non-natural amino acid composition (D-isomers, Aib, β-naphthylalanine) provides substantial resistance to proteolytic degradation. Reconstituted solutions are stable at 4°C for up to 7 days, with longer storage in aliquots at −20°C.

FOR RESEARCH USE ONLY. All compounds referenced in this article are supplied exclusively for in vitro and laboratory research by qualified scientists. Not intended for human or animal consumption, therapeutic use, or clinical application. Lone Star Peptide Co. makes no therapeutic claims regarding any compound referenced herein.

Ipamorelin Research: Selective GH Secretagogue and GHS-R1a Pharmacology